Fine specificity of equine infectious anaemia virus gp90-specific antibodies associated with protective and enhancing immune responses in experimentally infected and immunized ponies

References

1. Abacioglu Y. H., Fouts T. R., Laman J. D., Claassen E., Pincus S. H., Moore J. P., Roby C. A., Kamin-Lewis R., Lewis G. K. 1994; Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. AIDS Research and Human Retroviruses 10:371–381
   [Google Scholar]
2. Ball J. M., Rushlow K. E., Issel C. J., Montelaro R. C. 1992; Detailed mapping of the antigenicity of the surface unit glycoprotein of equine infectious anemia virus by using synthetic peptide strategies. Journal of Virology 66:732–742
   [Google Scholar]
3. Eaton A. M., Ugen K. E., Weiner D. B., Wildes T., Levy J. 1994; An anti-gp41 human monoclonal antibody that enhances HIV-1 infection in the absence of complement. AIDS Research and Human Retroviruses 10:13–18
   [Google Scholar]
4. Grund C. H., Lechman E. R., Issel C. J., Montelaro R. C., Rushlow K. E. 1994; Lentivirus cross-reactive determinants present in the capsid protein of equine infectious anaemia virus. Journal of General Virology 75:657–662
   [Google Scholar]
5. Hussain K. A., Issel C. J., Schnorr K. L., Rwambo P. M., Montelaro R. C. 1987; Antigenic analysis of equine infectious anemia virus (EIAV) variants by using monoclonal antibodies: epitopes of glycoprotein gp90 of EIAV stimulate neutralizing antibodies. Journal of Virology 61:2956–2961
   [Google Scholar]
6. Issel C. J., Horohov D. W., Lea D. F., Adams W. V., Hagius W. V., McManus J. M., Allison A. C., Montelaro R. C. 1992; Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus. Journal of Virology 66:3398–3408
   [Google Scholar]
7. Montelaro R. C., Bolognesi D. P. 1995; Retrovirus vaccines. In The Retroviridae vol 4 pp 605–656 Edited by Levy J. A. New York: Plenum;
   [Google Scholar]
8. Montelaro R. C., Ball J. M., Rushlow K. E. 1993; Equine retroviruses. In The Retroviridae vol 2 pp 257–360 Edited by Levy J. A. New York: Plenum;
   [Google Scholar]
9. Moore J., Lewis G. K., Robinson J. 1993a; Which gp160 vaccine?. Nature 361:503
   [Google Scholar]
10. Moore J., Lewis G. K., Robinson J. R. 1993b; Properties of an HIV vaccine. Nature 362:505–506
    [Google Scholar]
11. Pincus S. H., Messer K. G., Schwartz D. H., Lewis G. K., Graham B. S., Blattner W. A., Fisher G. 1993; Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. Journal of Clinical Investigation 91:1987–1996
    [Google Scholar]
12. Purtscher M., Trkola A., Gruber G., Buchacher A., Predl R., Steindl F., Tauer C., Berger R., Barrett N., Jungbauer A., Katinger H. 1994; A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Research and Human Retroviruses 12:1651–1658
    [Google Scholar]
13. Robinson W. E. Jr, Gorny M. K., Xu J. Y., Mitchell W. M., Zolla-Pazner S. 1991; Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro . Journal of Virology 65:4169–4176
    [Google Scholar]
14. Rwambo P. M., Issel C., Adams W. V., Hussain K., Miller M. A., Montelaro R. C. 1990; Equine infectious anemia virus (EIAV): humoral immune responses of recipient ponies and antigenic variation during persistent infection. Archives of Virology 111:199–212
    [Google Scholar]
15. Spear G. T., Takefman D. M., Sharpe S., Ghassemi M., Zolla-Pazner S. 1994; Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major portion of immune effector functions including complement activation, binding, and neutralization. Virology 204:609–615
    [Google Scholar]
16. VanCott T. C., Bethke F. R., Kalyanaraman V., Burke D. S., Redfield R. R., Birx D. L. 1994; Preferential antibody recognition of structurally distinct HIV-1 gp120 molecules. Journal of Acquired Immune Deficiency Syndromes 7:1103–1115
    [Google Scholar]
17. Volvowitz F., Smith G. 1993; Which AIDS vaccine?. Nature 362:504–505
    [Google Scholar]
18. Wang S. Z. S., Rushlow C. E., Issel C. J., Cook R. F., Cook S. J., Raabe M. L., Chong Y. H., Costa L., Montelaro R. C. 1994; Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein. Virology 199:247–251
    [Google Scholar]